当前位置: 首页 >> 检索结果
381. Cost-Effectiveness of Catheter Ablation Versus Antiarrhythmic Drug Therapy in Atrial Fibrillation: The CABANA Randomized Clinical Trial.
作者: Derek S Chew.;Yanhong Li.;Patricia A Cowper.;Kevin J Anstrom.;Jonathan P Piccini.;Jeanne E Poole.;Melanie R Daniels.;Kristi H Monahan.;Linda Davidson-Ray.;Tristram D Bahnson.;Hussein R Al-Khalidi.;Kerry L Lee.;Douglas L Packer.;Daniel B Mark.; .
来源: Circulation. 2022年146卷7期535-547页
In the CABANA trial (Catheter Ablation vs Antiarrhythmic Drug Therapy for Atrial Fibrillation), catheter ablation did not significantly reduce the primary end point of death, disabling stroke, serious bleeding, or cardiac arrest compared with drug therapy by intention-to-treat, but did improve the quality of life and freedom from atrial fibrillation recurrence. In the heart failure subgroup, ablation improved both survival and quality of life. Cost-effectiveness was a prespecified CABANA secondary end point.
382. Unblinded and Blinded N-of-1 Trials Versus Usual Care: A Randomized Controlled Trial to Increase Statin Uptake in Primary Care.
作者: Kate Tudor.;Jenny Brooks.;Jeremy Howick.;Robin Fox.;Paul Aveyard.
来源: Circ Cardiovasc Qual Outcomes. 2022年15卷6期e007793页
The aim was to assess whether an intervention incorporating a practicable open-label n-of-1 trial would lead to greater uptake of statin than usual care and comparable uptake to a closed-label gold-standard n-of-1 trial.
383. Vericiguat and Health-Related Quality of Life in Patients With Heart Failure With Reduced Ejection Fraction: Insights From the VICTORIA Trial.
作者: Javed Butler.;Amanda Stebbins.;Vojtěch Melenovský.;Nancy K Sweitzer.;Martin R Cowie.;Josef Stehlik.;Muhammad Shahzeb Khan.;Robert O Blaustein.;Justin A Ezekowitz.;Adrian F Hernandez.;Carolyn S P Lam.;Richard Nkulikiyinka.;Christopher M O'Connor.;Burkert M Pieske.;Piotr Ponikowski.;John A Spertus.;Adriaan A Voors.;Kevin J Anstrom.;Paul W Armstrong.; .
来源: Circ Heart Fail. 2022年15卷6期e009337页
We examined the effects of vericiguat compared with placebo in patients with heart failure with reduced ejection fraction enrolled in VICTORIA (Vericiguat Global Study in Patients With Heart Failure With Reduced Ejection Fraction) on health status outcomes measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) and evaluated whether clinical outcomes varied by baseline KCCQ score.
384. Cardiovascular Magnetic Resonance for Rejection Surveillance After Cardiac Transplantation.
作者: Chris Anthony.;Muhammad Imran.;Jim Pouliopoulos.;Sam Emmanuel.;James Iliff.;Zhixin Liu.;Kirsten Moffat.;Min Ru Qiu.;Catriona A McLean.;Christian Stehning.;Valentina Puntmann.;Vass Vassiliou.;Tevfik F Ismail.;Ankur Gulati.;Sanjay Prasad.;Robert M Graham.;Jane McCrohon.;Cameron Holloway.;Eugene Kotlyar.;Kavitha Muthiah.;Anne M Keogh.;Christopher S Hayward.;Peter S Macdonald.;Andrew Jabbour.
来源: Circulation. 2022年145卷25期1811-1824页
Endomyocardial biopsy (EMB) is the gold standard method for surveillance of acute cardiac allograft rejection (ACAR) despite its invasive nature. Cardiovascular magnetic resonance (CMR)-based myocardial tissue characterization allows detection of myocarditis. The feasibility of CMR-based surveillance for ACAR-induced myocarditis in the first year after heart transplantation is currently undescribed.
385. Frailty Status Modifies the Efficacy of Exercise Training Among Patients With Chronic Heart Failure and Reduced Ejection Fraction: An Analysis From the HF-ACTION Trial.
作者: Ambarish Pandey.;Matthew W Segar.;Sumitabh Singh.;Gordon R Reeves.;Christopher O'Connor.;Ileana Piña.;David Whellan.;William E Kraus.;Robert J Mentz.;Dalane W Kitzman.
来源: Circulation. 2022年146卷2期80-90页
Supervised aerobic exercise training (ET) is recommended for stable outpatients with heart failure (HF) with reduced ejection fraction (HFrEF). Frailty, a syndrome characterized by increased vulnerability and decreased physiologic reserve, is common in patients with HFrEF and associated with a higher risk of adverse outcomes. The effect modification of baseline frailty on the efficacy of aerobic ET in HFrEF is not known.
386. Sex Differences in Characteristics, Treatments, and Outcomes Among Patients Hospitalized for Non-ST-Segment-Elevation Myocardial Infarction in China: 2006 to 2015.
作者: Weihong Guo.;Xue Du.;Yan Gao.;Shuang Hu.;Yuan Lu.;Rachel P Dreyer.;Xi Li.;Erica S Spatz.;Frederick A Masoudi.;Harlan M Krumholz.;Xin Zheng.
来源: Circ Cardiovasc Qual Outcomes. 2022年15卷6期e008535页
Sex differences in clinical characteristics and in-hospital outcomes among patients with non-ST-segment-elevation myocardial infarction have been described in Western countries, but whether these differences exist in China is unknown.
387. Effects of Long-term Metformin and Lifestyle Interventions on Cardiovascular Events in the Diabetes Prevention Program and Its Outcome Study.
作者: Ronald B Goldberg.;Trevor J Orchard.;Jill P Crandall.;Edward J Boyko.;Matthew Budoff.;Dana Dabelea.;Kishore M Gadde.;William C Knowler.;Christine G Lee.;David M Nathan.;Karol Watson.;Marinella Temprosa.; .
来源: Circulation. 2022年145卷22期1632-1641页
Lifestyle intervention and metformin have been shown to prevent diabetes; however, their efficacy in preventing cardiovascular disease associated with the development of diabetes is unclear. We examined whether these interventions reduced the incidence of major cardiovascular events over a 21-year median follow-up of participants in the DPP trial (Diabetes Prevention Program) and DPPOS (Diabetes Prevention Program Outcomes Study).
388. Prognostic Role of Residual Thrombus Burden Following Thrombectomy: Insights From the TOTAL Trial.
作者: Mohammad Alkhalil.;Michał Kuzemczak.;Robin Zhao.;Charalampos Kavvouras.;Warren J Cantor.;Christopher B Overgaard.;Shahar Lavi.;Vinoda Sharma.;Saqib Chowdhary.;Goran Stanković.;Saško Kedev.;Ivo Bernat.;Ravinay Bhindi.;Tej Sheth.;Kari Niemela.;Sanjit S Jolly.;Vladimír Džavík.
来源: Circ Cardiovasc Interv. 2022年15卷5期e011336页
It is unclear whether more effective forms of thrombus removal than current aspiration catheters would lead to improved outcomes. We sought to evaluate the prognostic role of residual thrombus burden (rTB), after manual thrombectomy, in patients undergoing primary percutaneous coronary intervention with routine manual thrombectomy in the TOTAL trial (Thrombectomy Versus PCI Alone).
389. Understanding Baseline Physical Activity in Cardiac Rehabilitation Enrollees Using Mobile Health Technologies.
作者: Jessica R Golbus.;Kashvi Gupta.;Rachel Stevens.;V Swetha Jeganathan.;Evan Luff.;Thomas Boyden.;Bhramar Mukherjee.;Predrag Klasnja.;Sachin Kheterpal.;Sarah Kohnstamm.;Brahmajee K Nallamothu.
来源: Circ Cardiovasc Qual Outcomes. 2022年15卷7期e009182页
Baseline physical activity in patients when they initiate cardiac rehabilitation is poorly understood. We used mobile health technology to understand baseline physical activity of patients initiating cardiac rehabilitation within a clinical trial to potentially inform personalized care.
390. Pharmacogenomic Study of Statin-Associated Muscle Symptoms in the ODYSSEY OUTCOMES Trial.
作者: William A Murphy.;Nan Lin.;Amy Damask.;Gregory G Schwartz.;P Gabriel Steg.;Michael Szarek.;Poulabi Banerjee.;Sergio Fazio.;Garen Manvelian.;Robert Pordy.;Alan R Shuldiner.;Charles Paulding.
来源: Circ Genom Precis Med. 2022年15卷3期e003503页
Statin-associated muscle symptoms (SAMS) are the most frequently reported adverse events for statin therapies. Previous studies have reported an association between the p.Val174Ala missense variant in SLCO1B1 and SAMS in simvastatin-treated subjects; however, evidence for genetic predictors of SAMS in atorvastatin- or rosuvastatin-treated subjects is currently lacking.
391. Text Messages to Improve Medication Adherence and Secondary Prevention After Acute Coronary Syndrome: The TEXTMEDS Randomized Clinical Trial.
作者: Clara K Chow.;Harry Klimis.;Aravinda Thiagalingam.;Julie Redfern.;Graham S Hillis.;David Brieger.;John Atherton.;Ravinay Bhindi.;Derek P Chew.;Nicholas Collins.;Michael Andrew Fitzpatrick.;Craig Juergens.;Nadarajah Kangaharan.;Andrew Maiorana.;Michele McGrady.;Rohan Poulter.;Pratap Shetty.;Jonathon Waites.;Christian Hamilton Craig.;Peter Thompson.;Sandrine Stepien.;Amy Von Huben.;Anthony Rodgers.; .
来源: Circulation. 2022年145卷19期1443-1455页
TEXTMEDS (Text Messages to Improve Medication Adherence and Secondary Prevention After Acute Coronary Syndrome) examined the effects of text message-delivered cardiac education and support on medication adherence after an acute coronary syndrome.
392. Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial.
作者: Remo H M Furtado.;Itamar Raz.;Erica L Goodrich.;Sabina A Murphy.;Deepak L Bhatt.;Lawrence A Leiter.;Darren K McGuire.;John P H Wilding.;Philip Aylward.;Anthony J Dalby.;Mikael Dellborg.;Doina Dimulescu.;José C Nicolau.;Anthonius J M Oude Ophuis.;Avivit Cahn.;Ofri Mosenzon.;Ingrid Gause-Nilsson.;Anna Maria Langkilde.;Marc S Sabatine.;Stephen D Wiviott.
来源: Circulation. 2022年145卷21期1581-1591页
Dapagliflozin improved heart failure and kidney outcomes in patients with type 2 diabetes (T2DM) with or at high risk for atherosclerotic cardiovascular disease in the DECLARE-TIMI 58 trial (Dapagliflozin Effect on Cardiovascular Events - Thrombolysis in Myocardial Infarction 58). Here, the aim was to analyze the efficacy and safety of dapagliflozin stratified according to baseline systolic blood pressure (SBP).
393. First-Line Catheter Ablation of Monomorphic Ventricular Tachycardia in Cardiomyopathy Concurrent With Defibrillator Implantation: The PAUSE-SCD Randomized Trial.
作者: Roderick Tung.;Yumei Xue.;Minglong Chen.;Chenyang Jiang.;Dalise Y Shatz.;Stephanie A Besser.;Hongde Hu.;Fa-Po Chung.;Shiro Nakahara.;Young-Hoon Kim.;Kazuhiro Satomi.;Lishui Shen.;Er'peng Liang.;Hongtao Liao.;Kai Gu.;Ruhong Jiang.;Jian Jiang.;Yuichi Hori.;Jong-Il Choi.;Akiko Ueda.;Yuki Komatsu.;Shuichiro Kazawa.;Kyoko Soejima.;Shih-Ann Chen.;Akihiko Nogami.;Yan Yao.; .
来源: Circulation. 2022年145卷25期1839-1849页
Catheter ablation as first-line therapy for ventricular tachycardia (VT) at the time of implantable cardioverter defibrillator (ICD) implantation has not been adopted into clinical guidelines. Also, there is an unmet clinical need to prospectively examine the role of VT ablation in patients with nonischemic cardiomyopathy, an increasingly prevalent population that is referred for advanced therapies globally.
394. Intramural Needle Ablation for Refractory Premature Ventricular Contractions.
作者: Srinivas R Dukkipati.;Tomofumi Nakamura.;Ikutaro Nakajima.;Connor Oates.;Ryohsuke Narui.;Shinichi Tanigawa.;Tatjana Sljapic.;William Whang.;Jacob S Koruth.;Subbarao Choudry.;Benjamin Schaeffer.;Akira Fujii.;Usha B Tedrow.;John L Sapp.;William G Stevenson.;Vivek Y Reddy.
来源: Circ Arrhythm Electrophysiol. 2022年15卷5期e010020页
Frequent premature ventricular contractions (PVCs) are often amenable to catheter ablation. However, a deep intramural focus may lead to failure due to inability of standard ablation techniques to penetrate the focus. We sought to assess the efficacy and safety of infusion needle ablation (INA) for PVCs that are refractory to standard radiofrequency ablation.
395. Vitamin K2 and D in Patients With Aortic Valve Calcification: A Randomized Double-Blinded Clinical Trial.
作者: Axel C P Diederichsen.;Jes S Lindholt.;Sören Möller.;Kristian A Øvrehus.;Søren Auscher.;Jess Lambrechtsen.;Susanne E Hosbond.;Dilek H Alan.;Grazina Urbonaviciene.;Søren W Becker.;Maise H Fredgart.;Selma Hasific.;Lars Folkestad.;Oke Gerke.;Lars Melholt Rasmussen.;Jacob E Møller.;Hans Mickley.;Jordi S Dahl.
来源: Circulation. 2022年145卷18期1387-1397页
Menaquinone-7 (MK-7), also known as vitamin K2, is a cofactor for the carboxylation of proteins involved in the inhibition of arterial calcification and has been suggested to reduce the progression rate of aortic valve calcification (AVC) in patients with aortic stenosis.
396. Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF.
作者: Carly Adamson.;Kieran F Docherty.;Hiddo J L Heerspink.;Rudolf A de Boer.;Kevin Damman.;Silvio E Inzucchi.;Lars Køber.;Mikhail N Kosiborod.;Felipe A Martinez.;Mark C Petrie.;Piotr Ponikowski.;Marc S Sabatine.;Morten Schou.;Scott D Solomon.;Subodh Verma.;Olof Bengtsson.;Anna Maria Langkilde.;Mikaela Sjöstrand.;Muthiah Vaduganathan.;Pardeep S Jhund.;John J V McMurray.
来源: Circulation. 2022年146卷6期438-449页
In a post hoc analysis, the frequency of occurrence of an early decline (dip) in estimated glomerular filtration rate (eGFR) after initiation of dapagliflozin and its association with outcomes were evaluated in patients with heart failure and reduced ejection fraction randomized in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial.
397. Deep Lipidomics in Human Plasma: Cardiometabolic Disease Risk and Effect of Dietary Fat Modulation.
作者: Fabian Eichelmann.;Laury Sellem.;Clemens Wittenbecher.;Susanne Jäger.;Olga Kuxhaus.;Marcela Prada.;Rafael Cuadrat.;Kim G Jackson.;Julie A Lovegrove.;Matthias B Schulze.
来源: Circulation. 2022年146卷1期21-35页
In blood and tissues, dietary and endogenously generated fatty acids (FAs) occur in free form or as part of complex lipid molecules that collectively represent the lipidome of the respective tissue. We assessed associations of plasma lipids derived from high-resolution lipidomics with incident cardiometabolic diseases and subsequently tested if the identified risk-associated lipids were sensitive to dietary fat modification.
398. Relationship Between Social Vulnerability Indicators and Trial Participant Attrition: Findings From the HYVALUE Trial.
作者: Kamal H Henderson.;Laura J Helmkamp.;John F Steiner.;Edward P Havranek.;Suma X Vupputuri.;Rebecca Hanratty.;Irene V Blair.;Julie A Maertens.;Miriam Dickinson.;Stacie L Daugherty.
来源: Circ Cardiovasc Qual Outcomes. 2022年15卷5期e007709页
Social vulnerability indicators are associated with health care inequities and may similarly impede ongoing participation in research studies. We evaluated the association of social vulnerability indicators and research participant attrition in a trial focused on reducing health disparities.
399. Drug-Coated Balloon for Small Coronary Artery Disease in Patients With and Without High-Bleeding Risk in the BASKET-SMALL 2 Trial.
作者: Bruno Scheller.;Tuomas T Rissanen.;Ahmed Farah.;Marc-Alexander Ohlow.;Norman Mangner.;Jochen Wöhrle.;Sven Möbius-Winkler.;Daniel Weilenmann.;Gregor Leibundgut.;Florim Cuculi.;Nicole Gilgen.;Michael Coslovsky.;Felix Mahfoud.;Raban V Jeger.; .
来源: Circ Cardiovasc Interv. 2022年15卷4期e011569页
Patients at high-bleeding risk (HBR) undergoing percutaneous coronary intervention represent a challenging patient population. The use of drug-coated balloon (DCB) allows shorter duration of dual antiplatelet therapy compared with drug-eluting stents (DES) and reduces thrombotic risk due to the absence of a permanent implant. The present analysis aimed to investigate if the effect of DCB versus DES differed between patients with and without HBR treated with percutaneous coronary intervention in small coronary arteries.
400. Outcomes With Intermediate Left Main Disease: Analysis From the ISCHEMIA Trial.
作者: Sripal Bangalore.;John A Spertus.;Susanna R Stevens.;Philip G Jones.;G B John Mancini.;Jonathon Leipsic.;Harmony R Reynolds.;Matthew J Budoff.;Cameron J Hague.;James K Min.;William E Boden.;Sean M O'Brien.;Robert A Harrington.;Jeffrey S Berger.;Roxy Senior.;Jesus Peteiro.;Neeraj Pandit.;Leonid Bershtein.;Mark A de Belder.;Hanna Szwed.;Rolf Doerr.;Lorenzo Monti.;Khaled Alfakih.;Judith S Hochman.;David J Maron.; .
来源: Circ Cardiovasc Interv. 2022年15卷4期e010925页
Patients with significant (≥50%) left main disease (LMD) have a high risk of cardiovascular events, and guidelines recommend revascularization to improve survival. However, the impact of intermediate LMD (stenosis, 25%-49%) on outcomes is unclear.
|